Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy

摘要: What's known on the subject? and What does study add? Statins have shown broad spectrum anti-cancer properties in laboratory studies. In epidemiological studies, use of statins has been associated with reduced risk advanced prostate cancer. However, effects cancer disease progression following curative treatment not extensively studied, previous studies reported conflicting results. This found no clear association between overall statin progression, as well lack a monotone dose–response relationship statins, whether it was before or after prostatectomy, progression. Objective To investigate HMG-CoA reductase inhibitors (‘statins’), which is recurrence patients who undergo radical prostatectomy. Patients Methods All men incident diagnosed 2004 2005 subsequently underwent prostatectomy by end Kaiser Permanente Southern California (KPSC) health plan were identified using KPSC's registry. Subjects followed for up to 5 years (i) biochemical recurrence, defined single PSA measurement >0.2 ng/mL, (ii) clinical diagnosis metastatic prostate-cancer-related death. Information use, demographics, comorbidities, patho-clinical factors outcomes ascertained from electronic medical records. The prior both examined bivariate multivariate Cox models, adjusting prognostic factors. For postoperative exposure, time-dependent model used. Results A total 1200 included; 37% had preoperative 56% use. Neither nor (hazard ratio [HR] = 1.00 [0.72–1.39] 1.05 [0.76–1.46], respectively) (HR 0.63 [0.31–1.27] 1.20 [0.63–2.30], respectively). No duration use. Conclusions Statin may prevent prostatectomy. These findings do provide support pursuit prospective trial secondary prevention among surgically treated